GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

This long-acting antiretroviral medicine offers protection for six months at a time, providing a transformative alternative for millions. The post SA first in Africa to approve ‘most effective’ HIV ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...